Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05076487
Other study ID # PBRC 2021-022
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date November 29, 2023

Study information

Verified date December 2023
Source Pennington Biomedical Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this exploratory/developmental study is to investigate the episodic nature of food insecurity as a stressor via responses in body weight and psychological and physiological parameters longitudinally. Sixty African American women with obesity will be enrolled. Pennington Biomedical Research Center will coordinate this longitudinal study and measure 1) daily body weight remotely over 22 weeks and 2) psychological and physiological parameters via clinic assessments at the beginning and end of 22 weeks as well as assess episodes of food insecurity and stress on a weekly basis.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 29, 2023
Est. primary completion date November 29, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - willing to provide written informed consent - female - self-reported race of African American or more than one race in which African American is identified - 18 to 65 years of age - BMI 30 to 50 kg/m2 - reported income = 250% of the federal poverty level - ability to complete questionnaires in English - willing to archive blood and urine samples - willing to fast for a minimum of 8-10 hours prior to clinic visits Exclusion Criteria: - male - self-reported race other than African American or more than one race in which African America is not identified - reported income > 250% of the federal poverty level - given birth within the past 6 months, currently pregnant, or plans to become pregnant within 6 months - currently breastfeeding - currently participating in a weight loss program - current use of prescription or OTC medication specifically for weight loss - recent weight loss (+/-5% weight change in last 6 months by self-report). If ppt is on a prescription medication that impacts weight but meets weight stability criteria (+/-5% weight change in last 6 months by self-report), ppt will be deemed eligible - past bariatric surgery within the past 5 years or plans for bariatric surgery within 3 months - active cancer or cancer treatment - serious digestive disorders that significantly alter metabolism and weight (like uncontrolled inflammatory bowel disease) - other conditions that affect metabolism or body weight - current diagnosis and active treatment for alcoholism or other illicit drugs of abuse - uncontrolled significant thyroid disorder (controlled = 6 months of medication) - uncontrolled significant diabetes (FBS >250) or hypertension (BP >180/100) - current diagnosis or treatment for heart failure - serious psychiatric illness, including bipolar disorder and schizophrenia - current or recent diagnosis (within last 5 years) of an eating disorder - persons who weigh more than 380 pounds (due to scale) - not willing to be able to re-contacted - are unable to utilize devices and/or applications as required for study participation - have another member of the household (same address) that is a participant in RESPONSES - other conditions that affect metabolism or body weight as determined by the PIs and MI - presence of any cognitive, psychiatric, behavioral, or medical disorder that, in the opinion of the PIs or MI may interfere with study participation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Pennington Biomedical Research Baton Rouge Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body weight Change in body weight 22 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2